<DOC>
	<DOC>NCT02605538</DOC>
	<brief_summary>CF patients are at risk for hepatic disease. Vaccination is recommended to all CF patients according to European consensus. The aim of the study is to vaccinate as many patients as possible and to follow up whether immunization has been complete.</brief_summary>
	<brief_title>Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively</brief_title>
	<detailed_description>Initially, healthy volunteers will be vaccinated to be compared with patients' antibody response to hepatitis A and B vaccine. The connected part of this study is to vaccinate children suffering from latent tuberculosis against hepatitis B and to measure whether the immunization is related to specific interferon gamma response against Mycobacterium tuberculosis.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>CF patients not previously immunized against hepatitis A or B Healthy volunteers not previously immunized against hepatitis A or B Age over 1 year Previously transplanted patients Previous vaccination with hepatitis vaccine Known allergy against components in Twinrix (TM)</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>